Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Authors :: Lanino L
Restuccia F
Perego A
Ubezio M
Fattizzo B
Riva M
Consagra A
Musto P
Cilloni D
Oliva EN
Palmieri R
Poloni A
Califano C
Capodanno I
Itri F
Elena C
Fozza C
Pane F
Pelizzari AM
Breccia M
Di Bassiano F
Crisà E
Ferrero D
Giai V
Barraco D
Vaccarino A
Griguolo D
Minetto P
Quintini M
Paolini S
Sanpaolo G
Sessa M
Bocchia M
Di Renzo N
Diral E
Leuzzi L
Genua A
Guarini A
Molteni A
Nicolino B
Occhini U
Rivoli G
Bono R
Calvisi A
Castelli A
Di Bona E
Di Veroli A
Ferrara F
Fianchi L
Galimberti S
Grimaldi D
Marchetti M
Norata M
Frigeni M
Sancetta R
Selleri C
Tanasi I
Tosi P
Turrini M
Giordano L
Finelli C
Pasini P
Naldi I
Santini V
Della Porta MG
Source :: American journal of hematology [Am J Hematol] 2023 Aug; Vol. 98 (8), pp. E204-E208. Date of Electronic Publication: 2023 May 24.
Publication Year :: 2023

Subjects :: Humans
Activin Receptors, Type II
Immunoglobulin Fc Fragments
Myelodysplastic Syndromes drug therapy
Anemia, Sideroblastic drug therapy

Full Text Access

Tools